Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | NPM1 | P06748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22164963 | 0.87 | KDM4E (0.39) | KDM4EMAPTALDH1A1NSD2BACE1 | |
| SCHEMBL420104 | 0.84 | MAPT (0.61) | KDM4EMAPTALDH1A1NSD2BACE1 | |
| SCHEMBL23290978 | 0.79 | APP (0.58) | KDM4EMAPTALDH1A1MAOBRAB9A | |
| SCHEMBL422738 | 0.78 | KDM4E (0.50) | KDM4EMAPTALDH1A1NSD2BACE1 | |
| SCHEMBL31394603 | 0.77 | HDAC8 (0.38) | KDM4EMAPTALDH1A1BACE1HDAC8 | |
| SCHEMBL12940550 | 0.76 | KDM4E (0.49) | KDM4EMAPTALDH1A1NSD2BACE1 | |
| SCHEMBL13106149 | 0.76 | KDM4E (0.49) | KDM4EMAPTALDH1A1NSD2MAOA | |
| SCHEMBL653802 | 0.76 | KDM4E (0.72) | KDM4EMAPTALDH1A1NSD2BACE1 | |
| SCHEMBL13106147 | 0.76 | KDM4E (0.49) | KDM4EMAPTALDH1A1NSD2BACE1 | |
| SCHEMBL24814672 | 0.76 | KDM4E (0.49) | KDM4EMAPTALDH1A1NSD2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727939-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260014125-A1 | BICYCLIC-TYPE MAT2A INHIBITOR AND USE THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250214988-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2025-07-03 | — | — | US | disclosed |
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4556475-A1 | BICYCLIC-TYPE MAT2A INHIBITOR AND USE THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| CN-1653032-A | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2005-08-10 | — | — | CN | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
| US-6849649-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| CN-1492852-A | N-phenylpropylcyclopentyl substituted glutaramide derivatives as NEP inhibitors of FSAD | ������ҩ������˾ | 2004-04-28 | — | — | CN | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319676-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | NR1H4, FXR1, NR1H3 | KDM4E 3881/4885MAPT 2757/4885ALDH1A1 3644/4885 |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | KDM4E 1102/4885MAPT 4003/4885ALDH1A1 1289/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | KDM4E 43/4885MAPT 3740/4885ALDH1A1 1178/4885 |
| US-20260014125-A1 | BICYCLIC-TYPE MAT2A INHIBITOR AND USE THEREOF | MAT2A, MNAT1, MAT1A | KDM4E 2842/4885MAPT 1535/4885ALDH1A1 907/4885 |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | KDM4E 4744/4885MAPT 1208/4885ALDH1A1 2577/4885 |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | KDM4E 715/4885MAPT 3940/4885ALDH1A1 4211/4885 |
| US-20250214988-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | KDM4E 1531/4885MAPT 549/4885ALDH1A1 1032/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | KDM4E 1621/4885MAPT 3633/4885ALDH1A1 1008/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | KDM4E 2361/4885MAPT 4799/4885ALDH1A1 409/4885 |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | KDM4E 1218/4885MAPT 4378/4885ALDH1A1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.